Oncology and Hematology News and Journal Articles
Effective systemic therapy for the treatment of stage III melanoma has emerged. Whether this influences treatment choice in stage III melanoma patients with in-transit metastases is the subject of this review.
A study has shown a link between metabolic toxicities and the efficacy of mTOR inhibitors for the treatment of metastatic renal cell carcinoma.
This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer.
In prostate cancer patients, a PSA nadir value of > 0.5 ng/mL after radiation therapy and androgen deprivation therapy can identify patients at a high risk of death.
This video examines an exploratory analysis of the RESORCE trial, which tested regorafenib vs placebo in hepatocellular carcinoma patients following radiographic progression on sorafenib.
A multicenter study showed that an occurrence of posttransplant skin cancer was common among a group of organ transplant recipients.
The PD-1 inhibitor pembrolizumab showed promising antitumor activity and acceptable safety in patients with advanced urothelial cancer, in a phase I trial.
Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.
The journal ONCOLOGY includes a cartoon at the end of each issue. Here are the collected cartoons to date.